Müller glia in a mouse retina begin reprogramming after extracellular Prox1 is neutralized, leading to new neuron formation.
ANTI-PROX1 THERAPY REACTIVATES MAMMALIAN RETINAL REGENERATION
*Blocking Prox1 transfer unlocks Müller glia reprogramming in mice. The approach delays vision loss in a retinitis pigmentosa model, pointing to a new therapeutic avenue.*
Millions suffer from retinal degenerative diseases that strip away photoreceptors and ganglion cells, leaving vision irreversibly impaired. Unlike fish and amphibians, mammals cannot coax Müller glia—support cells that line the retina—into rebuilding lost neurons. The new Nature Communications study pinpoints a single protein, Prox1, as the roadblock. Prox1 builds up in Müller glia of both human and mouse retinas undergoing degeneration, yet it never appears in the regenerative zebrafish retina. The researchers traced the source of this protein to neighboring neurons, showing that it arrives via intercellular transfer. By cutting off that supply, they forced mouse Müller glia to revert to a progenitor state, sprouting new retinal cells and slowing vision loss in a retinitis pigmentosa model. The discovery reframes a long‑standing mystery about why mammalian eyes cannot heal themselves.
What is Prox1 and why does it matter?
Prospero‑related homeobox 1 (Prox1) is a transcription factor that accumulates in Müller glia (MG) of degenerating human and mouse retinas. It is absent from MG in regenerating zebrafish, highlighting a species‑specific barrier. In mammals, Prox1 presence correlates with the failure of MG to reprogram into retinal progenitor cells, a step required for neuron replacement. The study identifies Prox1 as the key inhibitory factor that distinguishes mammalian retinal degeneration from the robust regeneration seen in cold‑blooded vertebrates.
How does intercellular transfer of Prox1 block Müller glia?
In mouse retinas, Prox1 found in MG does not originate within the glia itself. Instead, it is transferred from neighboring retinal neurons via direct intercellular exchange. This external supply of Prox1 locks MG in a quiescent state, preventing the cell‑cycle re‑entry needed for progenitor formation. By disrupting the transfer pathway, researchers removed the inhibitory signal, allowing MG to adopt a progenitor identity and begin the regeneration cascade.
What experimental evidence shows anti‑Prox1 restores regeneration?
The team blocked Prox1 transfer in injured mouse retinas and observed MG reprogramming into retinal progenitor cells. They then delivered an anti‑Prox1 antibody using an adeno‑associated virus, which sequesters extracellular Prox1. This intervention promoted the generation of new retinal neurons and delayed vision loss in a mouse model of retinitis pigmentosa. The results demonstrate that neutralizing Prox1 can revive the dormant regenerative capacity of mammalian MG.
What are the implications for human vision loss?
Human retinal degenerative diseases, such as retinitis pigmentosa and glaucoma, currently lack treatments that restore lost neurons. By establishing Prox1 as a barrier and showing that anti‑Prox1 therapy can reactivate MG‑mediated regeneration in mice, the study opens a translational path toward human applications. If similar blockade can be achieved in patients, it could shift therapy from symptom management to genuine tissue repair, altering the prognosis for millions suffering vision loss.
Frequently asked questions
Why does Prox1 prevent retinal regeneration in mammals?
Prox1 accumulates in Müller glia of degenerating human and mouse retinas and originates from neighboring neurons via intercellular transfer, locking the glia in a non‑regenerative state.
How did researchers block Prox1 to restore regeneration?
They disrupted the intercellular transfer of Prox1 and delivered an adeno‑associated viral anti‑Prox1 antibody, which sequestered extracellular Prox1 and enabled Müller glia to become retinal progenitor cells.
What effect did anti‑Prox1 therapy have in a mouse model of retinitis pigmentosa?
The therapy promoted retinal neuron regeneration and delayed vision loss in the retinitis pigmentosa mouse model.
The anti‑Prox1 strategy transforms a molecular obstacle into a therapeutic lever. While the work remains pre‑clinical, it proves that mammalian retinal regeneration is not biologically impossible—only suppressed. Future trials will determine whether humans can safely replicate the blockade that rescued mouse vision. If successful, the approach could rewrite the treatment landscape for retinal blindness, turning a chronic, incurable condition into a manageable one.
Sources: Nature Communications article 'Restoration of retinal regenerative potential of Müller glia by disrupting intercellular Prox1 transfer' (https://www.nature.com/articles/s41467-025-58290-8)